Skip to main content
Premium Trial:

Request an Annual Quote

Pressure BioSciences Completes Second Tranche of Offering

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pressure BioSciences said after the close of the market Tuesday that it has completed the second tranche of its private placement raising gross proceeds of $275,475.

In the second tranche of the offering, the firm sold 22,038 units to two accredited investors for $12.50 per unit. Each unit consists of one share of Series C convertible preferred stock, which is convertible into 10 shares of common stock, and a warrant to purchase 10 shares of common stock at an exercise price equal to $2.13 per share, which is exercisable until the third anniversary of the date of issuance.

Pressure Bio disclosed in the filing with the US Securities and Exchange Commission that it had entered into an agreement with the investors to lower the price of the units from $15 each to $12.50 each. As a result, the firm issued an additional 11,011 units to investors who participated in the earlier closings on April 8 and April 11.

Pressure Bio has raised total gross proceeds of $1.1 million thus far from the private placement.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.